Skip to main content
REZNF logo

Street Capital Inc. (REZNF) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.01 $0.00 (0.00%)
MCap: $2.80M| Vol: 33.0K| 52-wk range: $0.0002 – $0.01

Market cap $2.80M is the value of all shares combined. Beta 0.74: the stock has moved about 26% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Street Capital Inc. (REZNF) trades at $0.01. Street Capital Inc. operates within the specialty and generic drug manufacturing sector. The company currently has a negative price-to-earnings ratio and profit margin. Market cap: $2.80M, Sector: Healthcare.

Price as of · Last analyzed: Mar 17, 2026
Street Capital Inc. operates within the specialty and generic drug manufacturing sector. The company currently has a negative price-to-earnings ratio and profit margin.

Analyst Coverage for REZNF: REZNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • YCBD · cbdMD, Inc. · 23 /100
  • AKAN · Akanda Corp. · 18 /100
  • QNTM · Quantum BioPharma Ltd. · 30 /100

See all scored stocks →

Street Capital Inc. (REZNF) Healthcare & Pipeline Overview

CEOChris Savoie
Employees72
HeadquartersToronto, CA
IPO Year2021

Street Capital Inc., a player in the specialty and generic drug manufacturing industry, faces challenges with profitability, indicated by its negative P/E ratio and profit margin. Operating within the healthcare sector, the company's performance is influenced by market dynamics and competitive pressures.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for REZNF?

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Street Capital Inc. presents a speculative investment opportunity within the specialty and generic drug manufacturing sector. With a market capitalization of $2.80M and a negative P/E ratio of -3.34, the company's financial performance raises concerns. However, a gross margin of 57.4% indicates potential in its core operations if profitability can be achieved. Key value drivers include successful development and commercialization of new drugs, strategic partnerships, and cost-efficiency improvements. Ongoing catalysts involve potential regulatory approvals and market expansion opportunities. Potential risks include competition, regulatory hurdles, and financial instability. Investors should closely monitor the company's progress in improving profitability and achieving sustainable growth.

Based on FMP financials and quantitative analysis

REZNF Key Highlights

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Market Cap of $2.80M indicates a small-cap company with potential for growth but also higher risk.

  • P/E Ratio of -3.34 suggests the company is currently not profitable.
  • Profit Margin of -75.8% highlights significant challenges in achieving profitability.
  • Gross Margin of 57.4% indicates a strong potential for profitability if operational efficiencies are improved.
  • Beta of 0.74 suggests the stock is less volatile than the overall market.

Who Are REZNF's Competitors?

REZNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
GCAN The Greater Cannabis Company, Inc. $1.60 0.00% —
YCBD cbdMD, Inc. $0.38 +1.42% $5.10M —
AKAN Akanda Corp. $3.43 -14.89% $9.05M —
QNTM Quantum BioPharma Ltd. $1.42 -6.58% $9.13M 30 5-pillar
BFRI Biofrontera Inc. $0.60 +1.10% $10.8M —
COSM COSM $2.87 -2.71% $14.4M —
SHPH Shuttle Pharmaceuticals Holdings, Inc. $3.90 +2.01% $18.6M 32 5-pillar
TXMD TherapeuticsMD, Inc. $1.81 -5.24% $21.0M 34 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are REZNF's Key Strengths?

Potential for high gross margin (57.4%).

  • Established presence in the Canadian market.
  • Focus on specialty and generic drugs.
  • Relatively low beta (0.74) indicating lower volatility.

What Are REZNF's Weaknesses?

Negative P/E ratio (-3.34) indicating lack of profitability.

  • Negative profit margin (-75.8%) indicating significant financial challenges.
  • Small market capitalization ($2.80M) limiting access to capital.
  • Limited information available about the company's operations.

What Could Drive REZNF Stock Higher?

Potential regulatory approvals for new drug formulations.

  • Strategic partnerships to expand market reach.
  • Cost-efficiency measures to improve profitability.

What Are the Key Risks for REZNF?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

  • Intense competition from larger pharmaceutical companies.
  • Regulatory hurdles and compliance requirements.
  • Pricing pressures and reimbursement challenges.
  • Negative P/E ratio and profit margin indicating financial instability.
  • Shell Risk detected.

What Are the Growth Opportunities for REZNF?

  • Expansion into New Therapeutic Areas: Street Capital Inc. can explore opportunities to expand its product portfolio into new therapeutic areas with unmet medical needs. This could involve developing or acquiring drugs targeting specific diseases or conditions, thereby increasing its market reach and revenue potential. The global market for specialty drugs is projected to reach $400 billion by 2028, presenting a significant growth opportunity for the company. Timeline: 2-3 years.
  • Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies or acquiring smaller, innovative drug developers can provide Street Capital Inc. with access to new technologies, products, and markets. This can accelerate its growth and enhance its competitive position. The pharmaceutical industry is witnessing increased consolidation, with mergers and acquisitions valued at over $200 billion annually. Timeline: 1-2 years.
  • Geographic Expansion into Emerging Markets: Expanding its geographic presence into emerging markets, such as Asia and Latin America, can provide Street Capital Inc. with access to new customer bases and growth opportunities. These markets are experiencing rapid growth in healthcare spending and demand for generic drugs. The emerging markets pharmaceutical market is projected to reach $500 billion by 2030. Timeline: 3-5 years.
  • Development of Proprietary Drug Formulations: Investing in the development of proprietary drug formulations or drug delivery technologies can differentiate Street Capital Inc. from its competitors and create a competitive advantage. This can involve developing novel formulations of existing drugs or improving drug delivery methods to enhance efficacy and patient compliance. The market for drug delivery technologies is projected to reach $100 billion by 2027. Timeline: 2-4 years.
  • Focus on Cost-Efficiency and Operational Excellence: Implementing cost-efficiency measures and improving operational excellence can enhance Street Capital Inc.'s profitability and competitiveness. This can involve streamlining manufacturing processes, optimizing supply chain management, and reducing administrative expenses. The pharmaceutical industry is facing increasing pressure to reduce costs and improve efficiency. Timeline: Ongoing.

What Are REZNF's Competitive Advantages?

  • Proprietary drug formulations or drug delivery technologies (if any).
  • Established relationships with wholesalers and distributors.
  • Regulatory expertise and compliance capabilities.
  • Cost-efficient manufacturing processes.

What Does REZNF Do?

Street Capital Inc. is a Canadian company operating in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic drugs. While detailed information regarding its founding story and evolution is not available, the company's current market position is characterized by a small market capitalization. Street Capital Inc.'s operations are influenced by the dynamics of the pharmaceutical industry, including regulatory requirements, research and development costs, and competition from other drug manufacturers. The company's geographic reach is primarily within Canada, and its competitive positioning is shaped by its ability to develop, manufacture, and market specialty and generic drugs effectively. The company's financial performance, as indicated by its negative profit margin, suggests potential challenges in achieving profitability within the competitive pharmaceutical landscape. Further details on specific products, services, and strategic initiatives are needed to provide a more comprehensive understanding of Street Capital Inc.'s operations and future prospects.

What Products and Services Does REZNF Offer?

  • Develops and manufactures specialty and generic drugs.
  • Markets and distributes pharmaceutical products.
  • Conducts research and development activities.
  • Seeks regulatory approvals for new drugs.
  • Forms strategic partnerships with other pharmaceutical companies.
  • Manages its supply chain and distribution network.
  • Monitors and complies with industry regulations.

How Does REZNF Make Money?

  • Develops or acquires rights to specialty and generic drug formulations.
  • Manufactures drugs in-house or through contract manufacturers.
  • Sells drugs to wholesalers, distributors, and pharmacies.
  • Generates revenue from drug sales.

What Industry Does REZNF Operate In?

Street Capital Inc. operates in the Drug Manufacturers - Specialty & Generic industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, regulatory scrutiny, and the need for continuous innovation. Market trends include increasing demand for generic drugs, rising healthcare costs, and advancements in drug delivery technologies. Street Capital Inc. competes with other generic drug manufacturers, as well as larger pharmaceutical companies. The company's success depends on its ability to develop and market cost-effective drugs, navigate regulatory hurdles, and maintain a competitive edge in the market.

Who Are REZNF's Key Customers?

  • Wholesalers and distributors of pharmaceutical products.
  • Pharmacies and retail drug stores.
  • Hospitals and healthcare providers.
  • Patients who purchase prescription drugs.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 17, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
F-Score 2/9

Financial Health

Street Capital Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

REZNF Valuation & Market Position

With a $2.80M market cap, Street Capital Inc. sits in the micro-cap segment of the market.

ROE 206%

Key Financial Metrics

Return on equity for Street Capital Inc. stands at 205.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.36 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -30.0%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Street Capital Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Chris Savoie. REZNF has traded publicly since 2021.

REZNF Financials

Bull Case vs Bear Case

Bull Case

  • Potential for high gross margin (57.4%).
  • Established presence in the Canadian market.
  • Focus on specialty and generic drugs.
  • Relatively low beta (0.74) indicating lower volatility.

Bear Case

  • Negative P/E ratio (-3.34) indicating lack of profitability.
  • Negative profit margin (-75.8%) indicating significant financial challenges.
  • Small market capitalization ($2.80M) limiting access to capital.
  • Limited information available about the company's operations.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

REZNF Latest News

No recent news available for REZNF.

REZNF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for REZNF.

Price Targets

Wall Street price target analysis for REZNF.

REZNF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for REZNF; grades run from A+ (80-100) to F (below 30).

Leadership: Chris Savoie

CEO

Chris Savoie serves as the CEO of Street Capital Inc. However, as CEO, he is responsible for leading the company's strategic direction, overseeing its operations, and driving its financial performance. His leadership is crucial in navigating the challenges and opportunities within the specialty and generic drug manufacturing industry.

Track Record: Information regarding Chris Savoie's specific achievements, strategic decisions, and company milestones under his leadership is not available. Assessing his track record requires further information on his tenure and the company's performance during his leadership.

REZNF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Street Capital Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and trading may be subject to greater risks and volatility compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier typically includes companies that are defunct, in bankruptcy, or unwilling to provide current information.

  • OTC Tier: OTC Other
Liquidity: Liquidity in OTC Other stocks like REZNF is typically very limited. Bid-ask spreads can be wide, and trading volume may be thin, making it difficult to buy or sell shares without significantly impacting the price. Investors should exercise caution due to the potential for price manipulation and illiquidity.
OTC Risk Factors:
  • Limited information and disclosure requirements.
  • Higher risk of fraud and manipulation.
  • Potential for delisting or suspension of trading.
  • Thin trading volume and wide bid-ask spreads.
  • Shell Risk Detected.
Due Diligence Checklist:
  • Verify the company's legal status and registration.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team and their track record.
  • Understand the risks associated with investing in OTC stocks.
  • Check for any regulatory actions or legal proceedings.
  • Consult with a financial advisor.
Legitimacy Signals:
  • Company has a functioning website.
  • Presence of a CEO and management team.
  • Operation in the healthcare sector.
  • Gross margin above zero.

Street Capital Inc. Healthcare Stock: Key Questions Answered

Is REZNF a good stock to buy?

Stock Expert AI does not rate REZNF buy, sell or hold. Street Capital Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the REZNF stock price today?

The last price recorded on this page for Street Capital Inc. (REZNF) is $0.01, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Street Capital Inc. do?

Street Capital Inc. operates within the healthcare sector, focusing on the development, manufacturing, and marketing of specialty and generic drugs. The company aims to provide cost-effective pharmaceutical products to meet the needs of patients and healthcare providers.

What are the key factors to evaluate for REZNF?

Evaluate REZNF on fundamentals, analyst consensus, and risk factors. Market Cap of $2.80M indicates a small-cap company with potential for growth but also higher risk. Not financial advice.

How frequently does REZNF data refresh on this page?

REZNF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven REZNF's recent stock price performance?

Street Capital Inc. (REZNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Potential for high gross margin (57.4%). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider REZNF overvalued or undervalued right now?

Street Capital Inc. (REZNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research REZNF before investing?

Before investing in Street Capital Inc. (REZNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available on Street Capital Inc. The analysis is based on the available data and may not reflect the company's complete situation.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives